Deals
By partnering with a UN-backed body, Roche has enabled companies to make the medicine for supply in 129 countries.
FEATURED STORIES
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Gilead, AstraZeneca and Vertex have acquired more than just a therapeutic asset in recent deals. BioSpace takes a look at five recent transactions where the staff was the real centerpiece.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The goal is to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.”
Shares of GenMark Diagnostics are soaring in premarket trading after Roche announced it was acquiring the California-based company in a $1.8 billion deal to bolster its own diagnostics pipeline.
The two pharmaceutical companies are going public and anticipate raising more than $250 million to advance research and development programs and support their business initiatives.
Here’s the scoop on IPO versus SPAC (Special Purpose Acquisition Corporation) from Paul Mieyal, life sciences investment guru.
The pair’s lead candidate, TAK-186 (formerly MVC-101), a first-in-class conditionally active T-cell engager, has recently entered the clinic in a Phase I/II study for the treatment of EGFR-expressing solid tumors such as those found in head and neck cancers.
Boston-based ABclonal Biotechnology acquired contract research organization (CRO) Yurogen Biosystems.
Shares of Five Prime Therapeutics were soaring this morning after Amgen announced it was acquiring the company and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion in cash.
If Resolution hits specified milestones, it’ll scoop up an extra $145 million from Agilent.
Beijing-based CRMO Pharmaron has accomplished impressive global growth via acquisitions over the past eight months.
The Silicon Therapeutics acquisition is designed to complement Roivant’s targeted protein degradation platform.